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Abstract In this report, we cloned a novel calmodulin-kinase
(CaM-KIN) from HeLa cells and characterized its activation
mechanism. CaM-KIN exhibits Ca2+/CaM-dependent activity
that is enhanced (V30-fold) in vitro by phosphorylation of its
Thr180 by CaM-K kinase (CaM-KK)K, consistent with detec-
tion of CaM-KIN-activating activity in HeLa cells. We also
identi¢ed a novel CaM-KKL isoform (CaM-KKL-3) in HeLa
cells whose activity was highly Ca2+/CaM-independent. Transi-
ently expressed CaM-KIN exhibited enhanced protein kinase
activity in HeLa cells without ionomycin stimulation. This sus-
tained activation of CaM-KIN was completely abolished by
Thr180Ala mutation and inhibited by CaM-KK inhibitor,
STO-609, indicating a functional CaM-KK/CaM-KIN cascade
in HeLa cells.
3 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Ca2þ/calmodulin-dependent protein kinases (CaM-Ks) are
implicated in the regulation of wide variety of biological
events that are mediated by intracellular Ca2þ including
muscle contraction, neurotransmitter release, and gene expres-
sion. Recent studies have demonstrated that two multifunc-
tional CaM-Ks, CaM-KI and IV are themselves activated by
the phosphorylation of a Thr residue in their activation loop
by an upstream CaM-K kinase (CaM-KK). This constitutes a
novel Ca2þ-signal transduction pathway, CaM-K cascade (re-
viewed in [1,2]). Two CaM-KK genes, CaM-KKK and CaM-
KKL, have been cloned in mammals and homologues have
been found in Caenorhabditis elegans and Aspergillus nidulans
[3^8].
It has been shown that CaM-KI is activated in response to
elevation of intracellular Ca2þ mediated by membrane depo-
larization in PC12 cells through phosphorylation by CaM-KK
[9]. We have also demonstrated that the CaM-KK mediated
activation of CaM-KI in C. elegans results in induction of
CREB-dependent transcription in transfected cells and in liv-
ing nematode [10,11]. Recently, Suizu et al. reported that the
activation of CaM-KK/CaM-KI cascade induces myosin II
phosphorylation at Ser19, resulting in regulation of actin ¢l-
ament organization in mammalian cells [12]. However, the
various physiological function(s) mediated by the mammalian
CaM-KK/CaM-KI cascade and the CaM-KK involved in reg-
ulating CaM-KI activity in vivo are not well understood.
In further characterizing CaM-KK/CaM-K cascade, we re-
port here the cloning of a novel human CaM-KI isozyme
(CaM-KIN) as well as a novel isoform of CaM-KKL in
HeLa cells. Furthermore, we characterized the activation of
CaM-KIN through phosphorylation by CaM-KK isoforms in
vitro and in transfected cells.
2. Materials and methods
2.1. Cloning of CaM-KIN and CaM-KKL-3
The method used to clone of CaM-KIN has been previously re-
ported [13]. Brie£y, a HeLa cDNA library in the VZAPII vector
was screened with a 1.0 kbp SalI/HindIII fragment derived from bo-
vine stomach MLCK (pSL17) under low stringency conditions, and
then the positive clone was subcloned into pBluescript SK(3). Clon-
ing of CaM-KKL-3 was performed by RT-PCR using random hex-
amer-primed cDNA prepared from HeLa cells as a template and
speci¢c primers for human CaM-KKL-1 (sense primer, 5P-CCAGT-
GTGCTGGATGAAGCTGGCGCATGC-3P ; antisense primer, 5P-
CACACGTGCTGGGTTTCCGTAGGACATGCT-3P ; nested prim-
er, 5P-CTATGGAAACGCGGTGCAGCAGCCCCCCAC-3P, [15]).
The ¢rst PCR was carried out using the sense and the antisense prim-
ers followed by the second PCR using the nested antisense primer. A
1.8 kbp PCR fragment contained a 1827 bp clone (CaM-KKL-3) and
a 1698 bp clone (CaM-KKL-3x). The nucleotide sequence data re-
ported in this paper appear in the DDBJ, EMBL and GenBank nu-
cleotide sequence databases under the accession number AB081726
(CaM-KIN), AB081336 (CaM-KKL-3) and AB081337 (CaM-KKL-
3x).
2.2. Construction and puri¢cation of recombinant CaM-KIN and
CaM-KKL-3
CaM-KIN cDNA was ampli¢ed by PCR using the sense primer, 5P-
GCTCTAGAGATGGCCCGGGAGAACGGCGAG-3P and the anti-
sense primer, 5P-CCGCTCGAGTCAGCTGAGGGATTCTGG-3P
and then ligated into the XbaI/XhoI sites of the pGEX-KG-PreS vec-
tor [14]. The Thr180Ala mutant of CaM-KIN was created by site-
directed mutagenesis using a mutagenic oligonucleotide (5P-AGTTC-
CACAGGCAGCGGACATCACATCTCC-3P). GST^CaM-KINs were
expressed in the Escherichia coli JM-109 by induction with 1 mM
IPTG and puri¢ed by glutathione^Sepharose column chromatogra-
phy. The cDNA of CaM-KKL-3 was introduced into pET-16b (No-
vagen). Recombinant CaM-KKL-3 was expressed in the E. coli strain
BL-21 (DE3) and puri¢ed by ProBond1 nickel-chelating resin (Invi-
0014-5793 / 03 / $22.00 K 2003 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
doi:10.1016/S0014-5793(03)00817-2
*Corresponding author. Fax: (81)-87-891 2368.
E-mail address: tokumit@kms.ac.jp (H. Tokumitsu).
Abbreviations: CaM-K, Ca2þ/calmodulin-dependent protein kinase;
HA, hemagglutinin
FEBS 27529 13-8-03
FEBS 27529 FEBS Letters 550 (2003) 57^63
Fig. 1. Cloning and mRNA expression pattern of human CaM-KIN. A: Nucleotide and deduced amino acid sequence of human CaM-KIN. B: Comparison of amino acid sequences of human
CaM-KIN, human CKLiK [20] and human CaM-KIK. Residues identical to human CaM-KIN are indicated with a dash and gaps in the alignment are indicated as a space. An asterisk indicates
the Thr180 residue in the activation loop. A catalytic domain is indicated with a box. A putative regulatory domain including autoinhibitory and CaM-binding regions is indicated with a dot.
C: RT-PCR analysis for human CaM-KIN was performed using speci¢c primers (underlined sequences in panel A) with cDNAs from HeLa cells (right panel) and human tissues (left panel). RT-
PCR for G3PDH (lower panel) was performed as a control experiment. M, 100 bp DNA ladder marker.
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trogen) followed by CaM^Sepharose chromatography according to
the manufacturer’s protocol.
2.3. RT-PCR analysis
RT-PCR analysis of CaM-KIN was performed with multiple human
tissue cDNA panels (Clontech) using 5P-CATGGATCGCTGGTGA-
CACAGCCCTCAACA-3P, and 5P-GGCCAGTCACTTGCTTCCA-
GAGTGCACTGC-3P as primers (Fig. 1A). PCR reaction was carried
out according to the manufacturer’s protocol using TITANIUM1
Taq DNA polymerase (Clontech).
2.4. Activation and phosphorylation of CaM-KIN in vitro
Either puri¢ed recombinant CaM-KKK (2.8 Wg/ml [14]) or HeLa
cell extract (0.5 mg/ml) was incubated with either 1.8 Wg GST^CaM-
KIN or the Thr180Ala mutant at 30‡C for 10 min in a solution (10 Wl)
containing 50 mM HEPES (pH 7.5), 10 mM Mg(Ac)2, 1 mM DTT,
either 200 WM ATP or 100 WM [Q-32P]ATP in the presence of either
1 mM EGTA or 1 mM CaCl2/10 WM CaM with 1 WM microcystin LR
(for treatment with HeLa cell extract). The reaction was initiated by
the addition of ATP and terminated by addition of SDS^PAGE sam-
ple bu¡er and then analyzed by SDS^PAGE followed by autoradiog-
raphy or terminated by dilution with 200 Wl of 50 mM HEPES, pH
7.5, 2 mg/ml bovine serum albumin, 10% ethylene glycol, and 1 mM
EDTA. Five Wl of the diluted sample (43 ng of CaM-KIN) was then
subjected to the protein kinase assay. CaM-KIN activity was measured
at 30‡C for 5 min using 40 WM syntide-2 as a substrate and 100 WM
[Q-32P]ATP (1000^2000 cpm/pmol) in the presence of either 1 mM
EGTA or 1 mM CaCl2/2 WM CaM as previously described [16]. Re-
sults represent the mean and standard error of the mean (S.E.M.) of
three experiments.
2.5. Transient expression and immunoprecipitation of hemagglutinin
(HA)-CaM-KIN and HA-CaM-KIV
Either HA-CaM-KIN or HA-CaM-KIV (2 Wg) was transfected into
HeLa and COS-7 cells with or without 1.5 Wg CaM-KKL-3-expressing
plasmid DNA and 20 Wg LipofectAMINE Reagent (Invitrogen) in
2.5 ml medium as previously described [17]. After 20 h incubation,
the cells were further cultured in serum-free medium for 6 h and then
treated with or without 1 WM ionomycin for 5 min. Stimulation was
terminated by the addition of 1 ml of lysis bu¡er and then HA-tagged
kinases were immunoprecipitated with 4 Wg of anti-HA antibody
(clone 12CA5, Roche Molecular Biochemicals) followed by measure-
ment of protein kinase activity in the presence of 100 WM [Q-32P]ATP,
1 mM CaCl2/2 WM CaM (or 1 mM EGTA for HA-CaM-KIN1-296)
and 10 Wg/ml STO-609 [17] using 40 WM syntide-2 as a substrate at
30‡C for 5 min [18]. Results represent the mean and S.E.M. of three
independent transfections.
2.6. CaM-KK activity assay
Activity of recombinant human CaM-KKL-3, CaM-KKL-3x or rat
CaM-KKK was measured by using 10 Wg GST^CaM-KI1-293, K49E
as a substrate and 100 WM [Q-32P]ATP in the presence of either 1 mM
EGTA or 1 mM CaCl2/2 WM CaM at 30‡C for 5 min [19].
3. Results and discussion
A HeLa cDNA library was screened under low stringency
conditions with a partial cDNA fragment derived from bovine
MLCK that contains both the catalytic and regulatory do-
mains [13]. This allowed us to isolate a 2235 bp clone encod-
ing a stretch of 385 amino acid residues (Fig. 1A) that shares
considerable homology with human CaM-KI (80% identity)
and that is strikingly similar to a CaM-KI like kinase
(CKLiK) that was originally identi¢ed as a granulocyte-spe-
ci¢c kinase [20] (Fig. 1B). It has been suggested that CKLiK
may play a role in transducing chemokine-induced signals
regulating human granulocyte functions [20]. Alignment of
the deduced amino acid sequences and the nucleotide sequen-
ces (data not shown) of both protein kinases reveals that their
catalytic domains and their putative regulatory domains, in-
cluding the CaM-binding site, are completely identical (Fig.
1B). However, their C-terminal tail regions after Cys347 dif-
fered. This sequence homology suggests that the CaM-depen-
dent kinase clone identi¢ed by our screening is likely a
C-terminal alternative spliced isoform of CKLiK. Based on
the structural similarity to CaM-KI family, we tentatively
termed the isolated clone as CaM-KIN. RT-PCR analysis re-
veals that in addition to HeLa cells, CaM-KIN possesses a
widespread tissue distribution but expressed very weak or un-
detectable levels in the heart, placenta and kidney (Fig. 1C).
Fig. 2. Activation and phosphorylation of CaM-KIN in vitro. A: Activation of CaM-KIN by CaM-KKK. Either GST^CaM-KIN wild-type
(WT) or Thr180Ala mutant (T180A) was incubated with (+) or without (3) puri¢ed recombinant CaM-KKK at 30‡C for 10 min with 200 WM
ATP in the presence of either 1 mM EGTA (3) or 1 mM CaCl2/10 WM CaM (+). After terminating the reaction, GST^CaM-KIN was sub-
jected to the protein kinase assay as described in Section 2 in the either presence of 1 mM EGTA (open bar) or 1 mM CaCl2/2 WM CaM
(closed bar). B: Phosphorylation of either GST^CaM-KIN wild-type (WT) or Thr180Ala mutant (T180A) by CaM-KKK was analyzed by
SDS^15% PAGE followed by autoradiography. C: Activation of CaM-KIN by HeLa cell extract. Either GST^CaM-KIN wild-type (WT) or
Thr180Ala mutant (T180A) was incubated with (+) or without (3) HeLa cell extract (0.5 mg/ml) and then subjected to the protein kinase as-
say.
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This result indicates that CaM-KIN may play a role in Ca2þ-
mediated regulation of the functions of various cells.
Since the activation loop of CaM-KIN contains the Thr180
residue involved in kinase activation (Fig. 1B), we assessed
whether the kinase activity of CaM-KIN could be activated
by a CaM-KK in vitro by using puri¢ed GST-fused CaM-
KIN. In the absence of CaM-KKK, CaM-KIN exhibited
Ca2þ/CaM-dependent kinase activity (34.5 U 2.0 nmol/min/
mg) (Fig. 2A). This activity was elevated approximately 30-
fold (979.2 U 43.4 nmol/min/mg) by treatment with CaM-KKK
in a Ca2þ/CaM-dependent manner (Fig. 2A), which was asso-
ciated with Thr180 phosphorylation by CaM-KKK (Fig. 2B).
Thus CaM-KKK can phosphorylate Thr180 in CaM-KIN, re-
sulting in a large induction of its catalytic e⁄ciency. Whereas
we observed Ca2þ/CaM-dependent autophosphorylation of
CaM-KIN, it had no impact on CaM-KIN activity (Fig. 2A,B).
In agreement with in vitro activation of CaM-KIN as shown
in Fig. 2A, we found that HeLa cell extract can activate CaM-
Fig. 3. Activation of CaM-KIN in transfected HeLa cells. A,B: HeLa cells were transfected with either empty vector (Mock), HA-CaM-KIN-ex-
pressing vector (A) or HA-CaM-KIV-expressing vector (B). After 20 h incubation, the cells were further cultured in serum-free medium for 6 h
and then treated with (+) or without (3) 1 WM ionomycin for 5 min and then immunoprecipitated samples were subjected to protein kinase as-
say in the presence of 1 mM CaCl2/2 WM CaM and 10 Wg/ml STO-609 [17] as described in Section 2. Immunoprecipitated samples (1/5 vol.)
were subjected to CaM-overlay in the presence of 1 mM CaCl2 (inset). Arrows indicate HA-CaM-KIN (A) and HA-CaM-KIV (B). C,D: E¡ect
of CaM-KK inhibitor, STO-609 on the activation of CaM-KIN in HeLa cells. HeLa cells were transfected with either empty vector (Mock),
HA-CaM-KIN-expressing vector (C) or HA-CaM-KIN 1-296-expressing vector (D) and then cultured for 20 h either with (+) or without (3)
10 Wg/ml STO-609 followed by culturing in serum-free medium for 6 h either with (+) or without (3) 10 Wg/ml STO-609. After treatment with
(+) or without (3) 1 WM ionomycin for 5 min (D) or no treatment (C), the cells were lysed and immunoprecipitated samples were subjected to
protein kinase assay as described above. Immunoprecipitated samples (1/5 vol.) were subjected to either CaM-overlay as described above (C in-
set) or Western blotting analysis using anti-HA antibody (D inset).
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Fig. 4. Cloning and characterization of human CaM-KKL-3. A: Nucleotide and deduced amino acid sequence of human CaM-KKL-3. B: Comparison of C-terminal amino acid sequences of hu-
man CaM-KKL-3, CaM-KKL-3x, CaM-KKL-1 and CaM-KKL-2 [15]. Residues identical to the human CaM-KKL-1 are indicated with a dash and gaps in the alignment are indicated as a dot.
Asterisks indicate a putative regulatory domain including autoinhibitory and CaM-binding regions. C: CaM-KK activity of either recombinant CaM-KKL-3 (0.32 Wg/ml) or rat CaM-KKK
(1.1 Wg/ml) was measured in the presence of either 1 mM EGTA (3) or 1 mM CaCl2/2 WM CaM (+) at 30‡C for 5 min. Recombinant CaM-KKL-3 (83 ng) and rat CaM-KKK (280 ng) were an-
alyzed by CaM-overlay as described in Fig. 3 (inset). D: Activation of CaM-KIN by CaM-KKL-3 in transfected COS-7 cells. COS-7 cells were transfected with either 3 Wg of empty vector
(Mock) or 1.5 Wg HA-CaM-KIN-expressing vector with 1.5 Wg empty pME18s vector or 1.5 Wg CaM-KKL-3-expressing vector. After 20 h incubation, the cells were further cultured in serum-free
medium for 6 h and then treated with (+) or without (3) 1 WM ionomycin for 5 min. HA-CaM-KIN was immunoprecipitated and then subjected to the protein kinase assay as described in Fig.
3B. Immunoprecipitated samples (1/5 vol.) were analyzed by CaM-overlay (inset). Arrow indicates HA^CaM-KIN.
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KIN wild-type but not Thr180Ala mutant (Fig. 2C), indicating
the presence of CaM-KIN-activating kinase in the cells. We
then further characterized the activation of CaM-KIN in intact
cells by transient transfection of HA-tagged CaM-KIN into
HeLa cells. In contrast to the parallel experiment using HA-
CaM-KIV, whose kinase activity was lowered by the serum
starvation and whose Ca2þ/CaM-dependent activity was sig-
ni¢cantly (8-fold) enhanced by ionomycin stimulation (Fig.
3B), CaM-KIN exhibited enhanced protein kinase activity
even without ionomycin stimulation (Fig. 3A). This suggests
that the CaM-KIN pool in HeLa cells is maintained in a par-
tially active form during the cell growth; however, ionomycin
treatment further enhanced CaM-KIN activity (1.5-fold). That
its sustained activation involves the phosphorylation of its
Thr180 residue is revealed by the assay with the Thr180Ala
mutant, which exhibited a reduced protein kinase activity that
was no longer induced by ionomycin stimulation (Fig. 3A).
Furthermore, enhanced activity of HA-tagged CaM-KIN in
resting cells was signi¢cantly reduced by treatment of the cells
with CaM-KK inhibitor, STO-609 after transfection (60^70%
inhibitory rate, Fig. 3C). Next we examined the mechanism of
this sustained activation of CaM-KIN by using a Ca2þ/CaM-
independent mutant (residues 1^296) which lacks putative
autoinhibitory and CaM-binding regions (Fig. 1B). Recombi-
nant CaM-KIN 1^296 phosphorylates the peptide substrate
(syntide-2) in a complete Ca2þ/CaM-independent manner
(data not shown). Immunoprecipitated HA-CaM-KIN 1-296
from transfected HeLa cells exhibited signi¢cantly increased
autonomous activity (Fig. 3D) that was no longer induced by
ionomycin stimulation unlike wild-type CaM-KIN (Fig. 3A).
This mutant CaM-KIN was apparently fully activated in rest-
ing HeLa cells by endogenous CaM-KK which is active with-
out Ca2þ-mobilization or is activated at resting Ca2þ levels,
since the increased autonomous activity of HA-CaM-KIN 1-
296 was inhibited by STO-609 treatment (75% inhibitory rate)
either with or without ionomycin stimulation. Taken together
these results, HeLa cells contain CaM-KK(s) that activate
CaM-KIN in both presence and absence of ionomycin stimu-
lation and the sustained activation of CaM-KIN is contributed
at least in part by Ca2þ-independent CaM-KK.
In order to identify the CaM-KK that activates CaM-KIN
in HeLa cells, we performed an RT-PCR that speci¢cally
ampli¢es CaM-KK isoforms using cDNA prepared from
HeLa cells as a template. As a result, we could detect CaM-
KKK in HeLa cells but two recently cloned isoforms of CaM-
KKL, CaM-KKL-1 and L-2 [15] have not been detected (data
not shown). However, we have isolated a novel CaM-KKL
isoforms from HeLa cells by RT-PCR using speci¢c 5P-UTR
and 3P-UTR sequences in CaM-KKL-1 as the PCR primers
and obtained two full-length clones. The 1.8 kb clone, as
shown in Fig. 4A,B, encodes a 541 amino acid protein that
lacks exon 16 [15] and therefore has a C-terminal sequence
that is distinct from that of CaM-KK L-1 and L-2 isoforms.
We therefore termed this novel splice isoform of CaM-KKL
as CaM-KKL-3. The nucleotide sequence of 1.7 kb clone re-
vealed that the clone is identical with CaM-KKL-3 except in
that it also lacks exon 14 [15], which encodes the C-terminus
of the catalytic domain as well as N-terminal half of the
regulatory domain (Leu442^Val484, [14]) (Fig. 4B). We de-
noted this splice isoform as CaM-KKL-3x. Isolation of the
full-length cDNAs of CaM-KKL-3 and CaM-KKL-3x in
this study is in good agreement with a recent ¢nding based
on RT-PCR ampli¢cation of partial cDNA fragments of
CaM-KKL, suggesting that the additional forms of CaM-
KKL transcripts are generated through alternative splicing
of the internal exons 14 and/or 16 [15]. RT-PCR analysis
indicated that both are expressed in all human peripheral
tissues we tested (data not shown) indicating that CaM-
KKL-3 is a non-neuronal CaM-KK and could be a candidate
of CaM-KIN activator.
Next we examined the activity and the Ca2þ/CaM-depen-
dency of CaM-KKL-3 by using GST^CaM-KI 1-293 K49E as
a substrate (Fig. 4C). Whereas CaM-KK activity of rat CaM-
KKK is completely dependent on Ca2þ/CaM, recombinant
CaM-KKL-3 showed enhanced autonomous activity (80% of
total activity). This is consistent with a previous observation
indicating an enhanced autonomous activity of rat CaM-KKL
[14]. Although CaM-KKL-3 exhibited an increased autono-
mous activity, activation of CaM-KIN by CaM-KKL-3 in vi-
tro was in a completely Ca2þ/CaM-dependent manner (data
not shown) as well as CaM-KKK (Fig. 2A), suggesting that
the Thr180 in CaM-KIN can not be accessed and phosphory-
lated by CaM-KKL-3 without binding of Ca2þ/CaM to CaM-
KIN, which is analogous to CaM-KI activation in vitro
[21,22].
Finally, we attempted to reconstitute CaM-KKL-3/CaM-
KIN cascade in transfected COS-7 cells (Fig. 4D). Similar to
what observed in transfected HeLa cells, HA-CaM-KIN is
maintained as an active form in transfected COS-7 cells
even without ionomycin stimulation. The addition of ionomy-
cin raised (V1.5-fold) CaM-KIN activity indicating that COS-
7 cells contain CaM-KIN-activating activity. When the COS-7
cells were cotransfected with vectors expressing HA-CaM-KIN
and CaM-KKL-3, CaM-KIN activity was raised to the level of
the ionomycin-induced CaM-KIN activity in single transfected
cells. This indicates that CaM-KKL-3 is capable of phosphor-
ylating and activating CaM-KIN in intact cells.
In summary, we have identi¢ed and cloned a novel human
member of the CaM-KI subfamily that we have denoted as
CaM-KIN. Here we have shown that CaM-KIN is activated by
CaM-KK through phosphorylation of Thr180 both in vitro
and in vivo. We observed the sustained activation of CaM-
KIN in intact cells, which is quite unlike the CaM-KIV acti-
vation. Based on our data, a part of CaM-KIN could be con-
stitutively activated at resting Ca2þ levels in the cells through
phosphorylation of Thr180 by CaM-KK. This is also consis-
tent with our ¢nding that resting HeLa cells contain CaM-
KIN-activating activity and CaM-KKL-3 exhibited enhanced
Ca2þ/CaM-independent activity. Taken together, CaM-KK/
CaM-KIN cascade is functionally operated in HeLa cells and
apparently involved in the sustained activation of CaM-KIN.
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